Apolipoprotein AI expression and high density lipoprotein distribution in transgenic mice during development

Area of Science:

• Biochemistry
• Molecular Biology
• Developmental Biology

Background:

• Apolipoprotein AI (apoAI) is a key component of high-density lipoprotein (HDL).
• Understanding the developmental regulation of apoAI and its impact on HDL is crucial for cardiovascular health.
• Previous studies have not fully elucidated the relationship between apoAI expression dynamics and HDL particle size during development.

Purpose of the Study:

• To investigate the developmental changes in apoAI expression in transgenic and nontransgenic mice.
• To determine the effect of these apoAI expression changes on high-density lipoprotein (HDL) particle sizes.
• To explore the role of post-transcriptional regulation in controlling plasma apoAI levels.

Main Methods:

• Utilized human apolipoprotein AI (apoAI) transgenic and nontransgenic control mice.
• Measured apoAI mRNA levels and plasma apoAI concentrations throughout development.
• Analyzed high-density lipoprotein (HDL) mass and particle size distribution using various analytical techniques.

Main Results:

• Both human and mouse apoAI mRNA levels increased post-delivery and decreased before weaning.
• Plasma apoAI concentration and HDL mass increased with age, remaining elevated in mature animals.
• Developmental increases in plasma apoAI correlated with increases in HDL particle sizes, with transgenic mice showing distinct HDL populations.

Conclusions:

• Post-transcriptional factors play a significant role in regulating plasma apoAI levels during development.
• Developmental changes in plasma apoAI concentrations are closely associated with alterations in HDL size distribution.
• These findings provide insights into the complex regulation of HDL metabolism during early life stages.